These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) announced today that Eventide Funds purchased 370,566 Common Shares from each of Marianne Sadar and Raymond Andersen, both...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 1,666,666 common shares...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the three months ended December 31, 2015. Amounts, unless specified otherwise, are expressed in
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce that it has completed its previously announced private placement (the "Private Placement") of 4,545,452...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI; NASDAQ: EPIX) announced today that Dr. David Parkinson has been appointed as the company's President and Chief Executive Officer effective...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) announced today its intention to complete a private placement (the "Private Placement") of 4,545,454 units of the Company (each,...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the year ended September 30, 2015. Amounts, unless specified otherwise, are expressed in...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI; NASDAQ: EPIX) announced today that the first patient has been enrolled in ESSA's Phase 1/2 clinical study of EPI-506 as a treatment for...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI; NASDAQ: EPIX) announced today that the Health Protection Branch ("HPB") of Health Canada has issued a 'no objection letter' for the Clinical...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI; NASDAQ: EPIX) announced today that the U.S. Food and Drug Administration ("FDA") has approved its Investigational New Drug ("IND") application...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the third quarter and three months ended June 30, 2015. Amounts, unless specified...
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) is pleased to announce that it has received final approval for its common shares to be listed and commence trading on the Toronto Stock...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that its common shares have been approved for listing and trading on the NASDAQ Capital Market ("NASDAQ") under the symbol...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that it has appointed Dr. David Parkinson to its board of directors. Dr. Parkinson's appointment as an independent director...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) today reported financial results for the second quarter and three and six months ended March 31, 2015. Amounts, unless specified otherwise,...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that it has received notification from the Food and Drug Administration ("FDA" or the "Agency") in the US that the Company's...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that it has filed with the Food and Drug Administration ("FDA") in the US an Investigation New Drug ("IND") application...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that it has appointed Mr. Franklin Berger to its board of directors. Mr. Berger's appointment as an independent director is...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) today reported financial results for the first quarter and three months ended December 31, 2014. Amounts, unless specified otherwise, are...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) and Bloom Burton & Co. Ltd. ("Bloom Burton") today announced that they have released from voluntary contractual lock-up (the "Lock-Up")...
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that it has submitted to the United States Securities and Exchange Commission ("SEC") a registration statement on Form 20-F...
/NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRES/ VANCOUVER, Jan. 27, 2015 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) announced today that the Company's...
ESSA Pharma Inc. ("ESSA" or the "Company") filed its financial and operating results today for the fourth quarter and the year ended September 30, 2014. ESSA's highlights for the fiscal year 2014...